Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Undersøgelse af PIT565 i recidiverende og/eller refraktære B-celle maligniteter

18. november 2026 opdateret af: Novartis Pharmaceuticals

En fase I, åben, multicenter undersøgelse af PIT565 hos patienter med recidiverende og/eller refraktære B-celle maligniteter

This is an open-label, multicenter, phase I study, which primary objective is to characterize the safety and tolerability of PIT565 and to identify maximal tolerated doses (MTDs) and/or recommended doses (RDs), schedule and route of administration in relapsed and/or refractory B-cell Non-Hodgkin lymphoma (R/R B-NHL) and relapsed and/or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL).

Studieoversigt

Status

Aktiv, ikke rekrutterende

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

This is an open-label, multicenter, phase I study of PIT565 in patients with R/R B-NHL and R/R B-ALL.

The study comprises a dose escalation part of PIT565 in two independent groups (group A: R/R B-NHL and B: R/R B-ALL) and a dose expansion part in three independent groups (R/R large B-cell lymphoma (LBCL) randomized in 1:1 ratio to two RDs (A1 and A2), and R/R B-ALL (B1)).

During the dose escalation, the safety (including the dose-dose limiting toxicity (DLT) relationship) and tolerability of PIT565 will be assessed, and schedule(s), route(s) of administration and dose(s) will be identified for use in the expansion part based on the review of these data. The RD will also be guided by the available information on pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity. The dose escalation will be guided by an adaptive Bayesian logistic regression model (BLRM) following the Escalation with Overdose Control (EWOC) principle.

Different schedules and routes of administrations will be explored in the dose escalation groups.

The dose expansion will further explore the MTD(s) and/or RD(s) and the selected schedule(s) and route of administration(s) in the three patients' groups.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

61

Fase

  • Fase 1

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • Ghent, Belgien, 9000
        • Novartis Investigative Site
    • Florida
      • Miami, Florida, Forenede Stater, 33136
        • University Of Miami
    • Illinois
      • Chicago, Illinois, Forenede Stater, 60637
        • University of Chicago Medical Center
    • Kansas
      • Fairway, Kansas, Forenede Stater, 66205
        • The University of Kansas Clinical Research Ctr
    • New York
      • New York, New York, Forenede Stater, 10065
        • Memorial Sloan Kettering Cancer Ctr
    • Oregon
      • Portland, Oregon, Forenede Stater, 97239
        • Oregon Health Sciences University
      • Créteil, Frankrig, 94010
        • Novartis Investigative Site
      • Marseille, Frankrig, 13273
        • Novartis Investigative Site
      • Tel Aviv, Israel, 6423906
        • Novartis Investigative Site
    • RE
      • Reggio Emilia, RE, Italien, 42123
        • Novartis Investigative Site
    • Chiba
      • Kashiwa, Chiba, Japan, 2778577
        • Novartis Investigative Site
      • Beijing, Kina, 100730
        • Novartis Investigative Site
      • Shanghai, Kina, 200032
        • Novartis Investigative Site
      • Tianjin, Kina, 300020
        • Novartis Investigative Site
      • Singapore, Singapore, 119074
        • Novartis Investigative Site
      • Singapore, Singapore, 169608
        • Novartis Investigative Site
      • Barcelona, Spanien, 08035
        • Novartis Investigative Site
      • Barcelona, Spanien, 08036
        • Novartis Investigative Site

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 100 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Signed informed consent must be obtained prior to participation in the study.
  • Male or female patients ≥18 years of age at the date of signing the informed consent form
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤2

NHL patient population

  • Refractory or relapsed B-NHL
  • Must have relapsed after or failed to respond to at least two prior treatment therapies including an αCD20 monoclonal antibody containing chemotherapy combination regimen
  • Must have at least one bi-dimensionally measurable nodal lesion or one bi-dimensionally measurable extranodal lesion, as measured on positron emission tomography-computed tomography (PET/CT) scan

ALL patient population

  • Refractory or relapsed CD19-positive B-ALL
  • Morphologic disease in the bone marrow (≥ 5% blasts)

Exclusion Criteria:

  • History of severe hypersensitivity to any ingredient of the study treatment or its excipients
  • Contraindication to tocilizumab
  • History of ongoing, chronic or recurrent infectious disease, or evidence of tuberculosis infection
  • Malignant disease, other than that being treated in this study. Exceptions to this exclusion include the following: malignancies that were treated curatively and have not recurred within 2 years prior to study treatment; completely resected basal cell and squamous cell skin cancers, and completely resected carcinoma in situ of any type
  • Active central nervous system (CNS) involvement by malignancy or presence of symptomatic CNS metastases, or CNS metastases that require local CNS-directed therapy (such as radiotherapy or surgery), or increasing doses of corticosteroids within the 2 weeks prior to the start of study treatment
  • Active, known or suspected autoimmune disease other than patients with vitiligo, residual hypothyroidism only requiring hormone replacement, psoriasis not requiring systemic treatment or conditions not expected to recur
  • Patients receiving systemic treatment with any immunosuppressive medication

Other protocol-defined inclusion/exclusion criteria may apply.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Ikke-randomiseret
  • Interventionel model: Sekventiel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: PIT565 Group A (dose escalation part)

PIT565 in adult NHL patients for whom two or more lines of chemotherapy have failed and either having progressed (or relapsed) after autologous hematopoietic stem cell transplantation (HSCT), or being ineligible for or not consenting to the procedure

Intravenous (i.v.) infusion or Subcutaneous (s.c.) injection

Eksperimentel: PIT565 Group B (dose escalation part)

PIT565 in adult R/R ALL patients.

Intravenous (i.v.) infusion or Subcutaneous (s.c.) injection

Eksperimentel: PIT565 Group A1 (dose expansion part)

PIT565 Recommended dose 1 (RD1) in adult R/R large B-cell lymphoma (LBCL) (DLBCL, double/triple hit High-grade B-cell lymphoma (HGBCL), Primary mediastinal large B-cell lymphoma (PMBCL), Follicular lymphoma grade 3B (FL3B)) patients.

Intravenous (i.v.) infusion or Subcutaneous (s.c.) injection

Eksperimentel: PIT565 Group A2 (dose expansion part)

PIT565 RD2 in adult R/R LBCL (DLBCL, double/triple hit HGBCL, PMBCL, FL3B) patients.

Intravenous (i.v.) infusion or Subcutaneous (s.c.) injection

Eksperimentel: PIT565 Group B1 (dose expansion part)

PIT565 in adult R/R ALL patients.

Intravenous (i.v.) infusion or Subcutaneous (s.c.) injection

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Incidence and severity of Dose Limiting Toxicities (DLTs)
Tidsramme: 28 days or 35 days, depending on the dosing schedule

Assessment of safety of study drug. A dose-limiting toxicity (DLT) is defined as an adverse event or abnormal laboratory value of CTCAE grade 3 or higher that occurs within the DLT evaluation period (28 days or 35 days depending on the schedule) and that is not primarily related to disease, disease progression, intercurrent illness, or concomitant medications with exceptions provided in the clinical protocol.

28 days or 35 days, depending on the dosing schedule
Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Tidsramme: 21 months

Assessment of safety of study drug.

21 months
Frequency of dose interruptions
Tidsramme: 21 months

Assessment of tolerability of study drug

21 months
Frequency of dose reductions
Tidsramme: 21 months

Assessment of tolerability of study drug

21 months
Dose intensities
Tidsramme: 21 months

Assessment of tolerability of study drug Dose intensity is defined as the ratio of actual cumulative dose received and actual duration of exposure.

21 months

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Overall Response Rate (ORR)
Tidsramme: 21 months

Evaluation of anti-tumor activity of PIT565 for Non-Hodgkin Lymphoma will be based on the Lugano Response Criteria Classification and anti-tumor activity of PIT565 for Acute Lymphoblastic Leukemia will be based on National Comprehensive Cancer Network (NCCN) 2018 v1 guidelines. Local investigator assessment will be used for analysis of efficacy endpoints.

21 months
Complete Response (CR) rate
Tidsramme: 21 months

Evaluation of anti-tumor activity of PIT565 for Non-Hodgkin Lymphoma will be based on the Lugano Response Criteria Classification and anti-tumor activity of PIT565 for Acute Lymphoblastic Leukemia will be based on National Comprehensive Cancer Network (NCCN) 2018 v1 guidelines. Local investigator assessment will be used for analysis of efficacy endpoints.

21 months
Best Overall Response (BOR)
Tidsramme: 21 months

Evaluation of anti-tumor activity of PIT565 for Non-Hodgkin Lymphoma will be based on the Lugano Response Criteria Classification and anti-tumor activity of PIT565 for Acute Lymphoblastic Leukemia will be based on National Comprehensive Cancer Network (NCCN) 2018 v1 guidelines. Local investigator assessment will be used for analysis of efficacy endpoints.

21 months
Duration Of Response (DOR)
Tidsramme: 21 months

Evaluation of anti-tumor activity of PIT565 for Non-Hodgkin Lymphoma will be based on the Lugano Response Criteria Classification and anti-tumor activity of PIT565 for Acute Lymphoblastic Leukemia will be based on National Comprehensive Cancer Network (NCCN) 2018 v1 guidelines. Local investigator assessment will be used for analysis of efficacy endpoints.

21 months
Overall Survival (OS)
Tidsramme: 33 months

Evaluation of anti-tumor activity of PIT565 for Non-Hodgkin Lymphoma will be based on the Lugano Response Criteria Classification and anti-tumor activity of PIT565 for Acute Lymphoblastic Leukemia will be based on National Comprehensive Cancer Network (NCCN) 2018 v1 guidelines. Local investigator assessment will be used for analysis of efficacy endpoints.

33 months
Progression Free Survival (PFS)
Tidsramme: 21 months

Evaluation of anti-tumor activity of PIT565 for Non-Hodgkin Lymphoma will be based on the Lugano Response Criteria Classification Local investigator assessment will be used for analysis of efficacy endpoints.

21 months
Event-free survival (EFS)
Tidsramme: 21 months

Evaluation of anti-tumor activity of PIT565 for Acute Lymphoblastic Leukemia will be based on National Comprehensive Cancer Network (NCCN) 2018 v1 guidelines. Local investigator assessment will be used for analysis of efficacy endpoints.

21 months
Maximum concentration of PIT565 (Cmax)
Tidsramme: 21 months

Pharmacokinetics (PK) parameters will be determined using non-compartmental method(s)

21 months
Area Under the Curve of PIT565 (AUC)
Tidsramme: 21 months

Pharmacokinetics (PK) parameters will be determined using non-compartmental method(s)

21 months
Trough concentration of PIT565 (C trough)
Tidsramme: 21 months

Pharmacokinetics (PK) parameters will be determined using non-compartmental method(s)

21 months
Prevalence of Anti-drug antibodies (ADA) at baseline
Tidsramme: Baseline

Assessment of anti-PIT565 antibodies in serum.

Baseline
Incidence of Anti-drug antibodies (ADA) on treatment
Tidsramme: 21 months

Assessment of anti-PIT565 antibodies in serum.

21 months

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

3. oktober 2022

Primær færdiggørelse (Anslået)

31. maj 2027

Studieafslutning (Anslået)

31. maj 2027

Datoer for studieregistrering

Først indsendt

25. maj 2022

Først indsendt, der opfyldte QC-kriterier

25. maj 2022

Først opslået (Faktiske)

31. maj 2022

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

19. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

18. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • CPIT565A12101
  • 2022-000367-45 (EudraCT nummer)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .